Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols®) with a 6-month follow up in previously treated patients with severe haemophilia B

Haemophilia

Volumn 15, Issue 6, 2009, Pages 1243-1248

  Aznar, J A ^a   Cabrera, N ^a   Matysiak, M ^b   Zawilska, K ^c   GErcheva, L ^d   Antonov, A ^e   Montan M ^f   Paez A M ^f   LIssitchkov, T ^g  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c J Strusia Hospital   (Poland)

^d UNIVERSITY HOSPITAL ST MARINA   (Bulgaria)

^e MEDICAL UNIVERSITY PLEVEN   (Bulgaria)

^f Parets del Vallès ^*  (Spain)

^g National Center of Hematology   (Bulgaria)

Author keywords

Factor IX; Factor IX Grifols ; Grifols; Haemophilia; Haemophilia B; Pharmacokinetics

Indexed keywords

BLOOD CLOTTING FACTOR 9 CONCENTRATE; FACTOR IX GRIFOLS; OCTANINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG PURITY; DRUG SAFETY; FOLLOW UP; HEMOPHILIA B; HUMAN; MALE; MEAN RESIDENCE TIME; OPEN STUDY; PRIORITY JOURNAL; SCHOOL CHILD; THROMBOSIS;

BLOOD COAGULATION FACTORS; FACTOR IX; FOLLOW-UP STUDIES; HALF-LIFE; HEMARTHROSIS; HEMOPHILIA B; HUMANS; MALE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70449576005     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02052.x     Document Type: Article

References (18)

1. Roberts HR, Eberts ME. Current management of hemophilia B. Hematol Oncol Clin North Am 1993, 7:1269-80.
2. Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med 1992, 326:800-6.
3. Roosendal G, Lafeber FP. Pathogenesis of haemophilic arthropathy. Heamophilia 2006, 12(Suppl. 3):117-21.
4. de Tezanos Pinto M, Fernandez J, Perez Bianco PR. Update of 156 episodes of central nervous system in haemophiliacs. Haemostasis 1992, 22:259-67.
5. Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 2003, 9:1-23.
6. Kim HC, Matts L, Eisele J, Czachur M, Saidi P. Monoclonal antibody-purified factor IX--comparative thrombogenicity to prothrombin complex concentrate. Semin Hematol 1991, 28(Suppl. 6):15-9.
7. Lowe GD. Factor IX and thrombosis. Br J Haematol 2001, 115:507-13.
8. Köhler M. Thrombogenicity of prothrombin complex concentrates. Thromb Res 1999, 95(Suppl. 1):S13-7.
9. Darby SC, Ewart DW, Giangrande PL. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 1997, 350:1425-31.
10. Schulman S, Wallensten R, White B, Smith OP. Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery. Haemophilia 1999, 5:96-100.
11. Note for Guidance on the clinical investigation of human plasma derived factor VIII and IX products. 2000, (CPMP/BPWP/198/95 rev.1), London, October 19th
12. White GC, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost 1997, 78:261-5.
13. Shapiro AD, Korth-Bradley J, Poon MC. Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia. Haemophilia 2005, 11:571-82.
14. White G, Shapiro A, Ragni M. Clinical evaluation of recombinant factor IX. Semin Hematol 1998, 35(Suppl. 2):33-8.
15. Ewenstein BM, Joist JH, Shapiro AD. Pharmacokinetic analysis of plasma-derived and recombinant FIX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 2002, 42:190-7.
16. Poon MC, Lillicrap D, Hensman C, Card R, Scully MF. Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study. Thromb Haemost 2002, 87:431-5.
17. Lee M, Morfini M, Negrier C, Chamouard V. The pharmacokinetic of coagulation factors. Haemophilia 2006, 12(Suppl. 3):1-7.
18. Warrier I, Ewenstein BM, Koerper MA. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Haematol Oncol 1997, 19:23-7.